About US
Contact us
>>Back
Lilly, BI approach CV-benefit label change for SGLT2 med Jardiance
- Publisher：
- Publication：2016/1/28
Eli Lilly ($LLY) and Boehringer Ingelheim are one step closer to an important label change for SGLT2 contenderJardiance. The FDA has accepted a supplemental New Drug Application that, if approved, will allow reps to tout study data showing the med can cut cardiovascular risks in Type 2 diabetes patients.